DIAアカウントをお持ちの場合、サインインしてください。

サインイン

ユーザーIDをお忘れですか? or パスワードをお忘れですか?

Holiday Inn London Kensington Forum

2016年6月14日 (火) 午後 12:30 - 2016年6月15日 (水) 午後 4:30

97 Cromwell Road, London, SW7 4DN, United Kingdom

DILI: Clinical Trials and Post-Marketing

This course is led by a Hepatologist with extensive experience in clinical assessment of DILI and who published ‘RUCAM’ the widely used causality assessment method of DILI.

学部

Gaby L. Danan, MD, PHD

Gaby L. Danan, MD, PHD

Pharmacovigilance Expert, GLD, France

Gaby Danan, MD, PhD, was the EU QPPV for Sanofi until his retirement in 2010. He has served on the Council for International Organizations of Medical Sciences and International Conference on Harmonisation Expert Working Groups, as the European Federation of Pharmaceutical Industries and Associations Clinical Safety E2B topic leader and co-chaired the EudraVigilance Expert Working Group from its inception until 2009. Dr. Danan co-published the Roussel Uclaf Causality Assessment Method for drug-induced liver injury, has authored papers on pharmacovigilance definitions and methodologies, chaired the DIA 2010 Annual Meeting, serves on the DIA Safety Training Committee, and instructs several DIA training courses.

最新情報や機会を逃さないで

DIAのメールを購読すれば、常に最新の業界情報やイベント情報を得ることができます。